Literature DB >> 4071369

Characterization of a modified, stroma-free hemoglobin solution as an oxygen-carrying plasma substitute.

N Kothe, B Eichentopf, K Bonhard.   

Abstract

A new infusion solution prepared from stroma-free, crosslinked and pyridoxalated hemoglobin is described. The characteristics of which have been adapted to the functions of native, intra-erythrocyte hemoglobin. The solution contains 8.5 per cent weight per volume of glutardialdehyde modified hemoglobin with a mean molecular weight (Mn) of 200,000 Dalton. The non-crosslinked fraction constitutes 15 per cent of the total hemoglobin. The p50 of 27 torr at pH 7.4 (plasma pH) corresponds to the value for the intra-erythrocyte hemoglobin at pH 7.25. The oncotic pressure is adjusted to 28 torr by the addition of 2.5 per cent weight per volume of human albumin. The methemoglobin content is less than 5 per cent of the total hemoglobin and remains constant for one year. The relative viscosity of the 8.5 per cent hemoglobin solution is 3.0 and, thus, is lower than the viscosity of blood. The intravascular half-life was determined in chimpanzees as about 16 hours. On the basis of available data, this hemoglobin solution may be suitable for clinical use as oxygen carrying plasma substitute.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4071369

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

Review 1.  Blood transfusion: yesterday, today, and tomorrow.

Authors:  W J Rudowski
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

2.  Oxygen transport by a modified haemoglobin solution (PPSFH) in a dog model of acute anaemia following hypovolaemia.

Authors:  D Gilroy; W Odling-Smee
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Pyridoxylated polymerized hemoglobin solution processing. Interest of a membrane molecular fractionation step.

Authors:  Y Clerc; M Dubos; N Bihoreau; L Delamourd; C Brasseur; B Gond; M Goyffon; J Saint-Blancard
Journal:  Appl Biochem Biotechnol       Date:  1987-04       Impact factor: 2.926

Review 4.  Nanomedicines: A Potential Treatment for Blood Disorder Diseases.

Authors:  Nan Zhang; Ming-Yuan Wei; Qiang Ma
Journal:  Front Bioeng Biotechnol       Date:  2019-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.